Q2 EPS Estimates for IceCure Medical Lowered by Analyst

IceCure Medical Ltd. (NASDAQ:ICCM) – Investment analysts at Brookline Capital Markets reduced their Q2 2026 earnings per share estimates for shares of IceCure Medical in a note issued to investors on Tuesday, May 12th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings of ($0.06) per share for the quarter, down from their prior estimate of ($0.03). The consensus estimate for IceCure Medical’s current full-year earnings is ($0.12) per share. Brookline Capital Markets also issued estimates for IceCure Medical’s FY2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.10) EPS and FY2028 earnings at ($0.07) EPS.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.03). IceCure Medical had a negative return on equity of 222.27% and a negative net margin of 441.60%.The firm had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $1.34 million.

Other analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Alliance Global Partners began coverage on shares of IceCure Medical in a report on Monday, May 4th. They set a “buy” rating for the company. Maxim Group decreased their target price on shares of IceCure Medical from $3.00 to $1.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $2.09.

IceCure Medical Trading Up 1.7%

Shares of NASDAQ:ICCM opened at $0.24 on Friday. IceCure Medical has a twelve month low of $0.22 and a twelve month high of $1.40. The company’s 50 day moving average is $0.41 and its 200 day moving average is $0.57. The company has a market cap of $19.58 million, a PE ratio of -1.00 and a beta of 0.47.

Institutional Investors Weigh In On IceCure Medical

Several hedge funds have recently bought and sold shares of ICCM. Concurrent Investment Advisors LLC purchased a new position in shares of IceCure Medical during the 4th quarter valued at approximately $48,000. Virtu Financial LLC purchased a new stake in IceCure Medical during the fourth quarter worth $39,000. Finally, Jane Street Group LLC acquired a new stake in IceCure Medical during the fourth quarter valued at $67,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

IceCure Medical News Summary

Here are the key news stories impacting IceCure Medical this week:

• Positive Sentiment: Nasdaq granted IceCure Medical an additional 180-day period, until November 9, 2026, to regain compliance with the minimum bid price requirement, which reduces near-term delisting risk. IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
• Neutral Sentiment: Maxim Group kept a buy rating on IceCure Medical but cut its price target from $3.00 to $1.00, signaling more limited upside than before. Benzinga report on Maxim Group price target cut
• Neutral Sentiment: Additional coverage also showed a lower price target estimate for ICCM, reinforcing the view that analysts see less value in the stock than previously expected. MSN report on price target decrease
• Negative Sentiment: Brookline Capital Markets lowered its earnings estimates for IceCure Medical across multiple periods, including Q2 2026, FY2026, FY2027, FY2028 and FY2029, reflecting expectations for continued losses and weaker profitability. Brookline Capital Markets estimate revisions for IceCure Medical

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.